In other series (including a systematic review) evaluating EGFR TKI trials (N = 1196) and several retrospective series evaluating patients (N = 126–1081) treated with EGFR TKI, the percentage of patients with bone metastases at diagnosis of metastatic NSCLC was similar to our study (Supplementary Table 1).11 This evidence concerns the gene EGFR and non-small cell lung carcinoma.